Biosynex SA (EPA:ALBIO)

France flag France · Delayed Price · Currency is EUR
0.932
-0.008 (-0.85%)
Feb 27, 2026, 5:35 PM CET
-26.61%
Market Cap 17.47M
Revenue (ttm) 97.95M
Net Income (ttm) -70.99M
Shares Out 18.75M
EPS (ttm) -4.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 7,926
Average Volume 25,328
Open 0.940
Previous Close 0.940
Day's Range 0.932 - 0.940
52-Week Range 0.455 - 1.980
Beta 0.83
RSI 50.36
Earnings Date Apr 30, 2026

About Biosynex

Biosynex SA designs, manufactures, and distributes rapid diagnostic tests to patients and healthcare professionals in France and internationally. The company develops and markets IVDs in the form of RDTs and TRODs, immunoblot, molecular biology, and POC for screening, diagnosis, and prevention. It also provides thermometers, tensiometers, oximetry, hearing protection products, oral and dental hygiene products, self-tests, thermal pads, inhalation chambers, and thermotherapy products. The company was founded in 1993 and is based in Illkirch-Graf... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 1993
Employees 454
Stock Exchange Euronext Paris
Ticker Symbol ALBIO
Full Company Profile

Financial Performance

In 2024, Biosynex's revenue was 101.17 million, an increase of 8.81% compared to the previous year's 92.98 million. Losses were -43.33 million, 17.3% more than in 2023.

Financial Statements

News

There is no news available yet.